

Press Releases (From April 1, 2020 to May 31, 2021)

2021


Business Development	May 19	New collaboration with Glaukos to develop and commercialize STN2000100 (DE-128) in the Americas, Australia and New Zealand
Sustainability	May 18	Establishment of "Santen Vision for the Earth 2050"
Sustainability	May 17	Joined the "30% Club Japan" to increase gender diversity Becoming a signatory of the "UN Women's Empowerment Principles"
Management	May 11	Postponement of transition to a holding company structure through sole-share transfer and change in Fiscal Year
Management	Apr. 22	Commenced the construction of new factory in Suzhou, China
Management	Apr. 9	Notice of recording of impairment loss and revision of Full-Year earnings forecasts
Management	Feb. 4	Commencement of preparation for transition to a holding company structure through sole-share transfer and change in Fiscal Year
Products	Feb. 2	U.S. FDA acceptance of new drug application for STN1011700 (DE-117) as a treatment for patients with glaucoma and ocular hypertension
Products	Feb. 1	Launch of glaucoma and ocular hypertension treatment <i>EYBELIS Ophthalmic Solution 0.002%</i> in South Korea
Sustainability	Jan. 7	Santen joins the Valuable 500 International Initiative promoting the active participation of people with disabilities

2020

Products	Nov. 5	Santen releases <i>LENTIS Comfort Toric</i> in Japan, a multifocal IOL covered under the Japanese health insurance program for cataract patients with astigmatism
Business Development	Oct. 28	Santen and Aerie conclude exclusive license agreement for <i>Rhopressa</i> and <i>Rocklatan</i> in Japan and several other Asian countries
Sustainability	Oct. 28	Santen, JBFA and IBF Foundation form a 10-Year, long-term partnership for an inclusive society
Management	Oct. 20	Establishment of holding company in China

Business Development	Oct. 8	Santen and Orbis International announce long-term partnership to tackle the increasing burden of eye diseases
Management	Sep. 17	Santen and U.S. ophthalmic company Eyevance enter into share purchase agreement
Sustainability	Sep. 10	Santen decides to offer special sponsorship for continued activities of men's and women's National Blind Football Teams
Sustainability	Aug. 11	Santen and International Blind Sports Federation forge partnership through blind sports
Business Development	Jul. 28	Santen and RVL Pharmaceuticals, Inc., an Osmotica Company, enter into an exclusive license agreement in Japan, Asia, and EMEA for RVL-1201, a treatment for acquired blepharoptosis
Products	Jul. 7	U.S. FDA acceptance of Premarket Approval (PMA) application for STN2000100 (DE-128) for review
Management	Jul. 7	Santen introduces its new corporate brand name notation and corporate slogan aiming to grow on a globally, going beyond the pharmaceutical industry
Management	Jul. 7	Announcement of new vision aiming to resolve social issues related to the eye health of people around the world
Business Development	Jun. 30	Strategic alliance with Plano to tackle the global burden of myopia
Business Development	Jun. 18	Santen and Orbis International join forces to expand access to training for eye care professionals through telemedicine platform
Products	Jun. 5	Bayer Yakuin and Santen launch <i>EYLEA Intravitreal Injection KIT 40mg/mL</i> , pre-filled syringe of intravitreal VEGF inhibitor <i>EYLEA</i>
Business Development	May 8	Santen and jCyte conclude an exclusive licensing contract in Japan, Asia and Europe for the jCell therapy program for retinitis pigmentosa
Sustainability	Apr. 28	Support for people with visual impairments facing the COVID-19 pandemic, together with the Japan Blind Football Association
Sustainability	Apr. 27	Santen introduces eco-friendly biomass plastic eyedrop bottles

See the Santen website for all press releases.

 https://www.santen.com/en/news/2021_1.jsp



Stock Information (As of March 31, 2021)

Major Shareholders (Top 10)

Name / Company Name	Number of Shares Owned (1,000 shares)	Holding Ratio (%)
STATE STREET BANK AND TRUST COMPANY 505223	33,829	8.4
Custody Bank of Japan, Ltd. (Trust account)	33,252	8.3
The Master Trust Bank of Japan, Ltd. (Trust account)	31,781	7.9
Nippon Life Insurance Company	10,662	2.7
MUFG Bank, Ltd.	10,605	2.6
Ono Pharmaceutical Co., Ltd.	8,790	2.2
Custody Bank of Japan, Ltd. (Trust account 7)	8,599	2.1
Custody Bank of Japan, Ltd. as trustee for Eisai Co., Ltd. Retirement Benefit Trust Account re-entrusted by Mizuho Trust & Banking Co., Ltd.	6,863	1.7
RBC IST 15 PCT LENDING ACCOUNT - CLIENT ACCOUNT	6,654	1.7
STATE STREET BANK WEST CLIENT - TREATY 505234	6,303	1.6

Yearly High and Low Prices (JPY)


FY	2016	2017	2018	2019	2020
High	1,749	1,946	2,061	2,234	2,216
Low	1,251	1,463	1,450	1,408	1,370

Total Shareholders Return


FY	2016	2017	2018	2019	2020
Total shareholders return (%)	96.8	104.4	102.0	115.9	97.8
Comparative index: TOPIX including dividends (%)	114.7	132.9	126.2	114.2	162.3

Composition of Shareholders


By number of shares




By number of shareholders



Stock Price Range (JPY)



Trading Volume (Thousands of shares)



Press Releases, Stock Information, Corporate Information

Corporate Information (As of March 31, 2021)

Corporate Headquarters	Santen Pharmaceutical Co., Ltd. Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka 530-8552, Japan TEL: +81-6-7664-8621
Website	https://www.santen.com/en/
Established	1890
Paid-in Capital	JPY 8,525 million

Number of Employees	4,229 (consolidated)
Number of Shares Issued	400,368,954
Number of Shareholders	24,827
Stock Exchange Listing	Tokyo Stock Exchange
Ticker Code	4536
Shareholder Registry Administrator	Mitsubishi UFJ Trust and Banking Corporation
Transfer Agent	6-3, Fushimi-cho 3-chome, Chuo-ku, Osaka 541-8502, Japan


Website

Please refer to Santen's website for more detailed information on each section of this report.

- Corporate Website
<https://www.santen.com/en/>






- IR Website
(subsection of corporate website)
<https://www.santen.com/en/ir/>






- Sustainability Website
(subsection of corporate website)
<https://www.santen.com/en/sustainability/>



Inclusion in ESG Indexes

Index Name	Overview
FTSE4Good Index Series 	Index Series developed by FTSE Russell of the U.K. The index series selects companies based on evaluations of their initiatives in the areas of Environmental, Social and Governance (ESG) activities.
FTSE Blossom Japan Index 	A broad index developed by FTSE Russell of the U.K. The index incorporates overall ESG considerations.
MSCI Japan ESG Select Leaders Index 	An index developed by MSCI of the U.S. The index selects companies based on high ESG ratings in their respective industries.

Index Name	Overview
MSCI Japan Empowering Women Index (WIN) 	An index developed by MSCI of the U.S. The index selects companies in various sectors that excel in gender diversity from among the top 700 Japanese stocks by market capitalization.
SOMPO Sustainability Index 	An index composed of corporations that achieved above-standard ESG scores in corporate surveys conducted by Sompo Risk Management & Health Care Inc. (in terms of E: environmental assessments) and by Integrex Inc. (in terms of S and G: social and corporate governance assessments).
S&P/JPX Carbon Efficient Index 	An index developed by S&P Dow Jones Indices of the U.S. The index evaluates corporate performance in terms of disclosure of information carbon efficiency.

FTSE Russell (the trading name of FTSE International Limited and Frank Russell Company) confirm that Santen Pharmaceutical has been independently assessed according to the FTSE4 Good criteria, and has satisfied the requirements to become a constituent of the FTSE4Good Index Series. Created by the global index provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good indices are used by a wide variety of market participants to create and assess responsible investment funds and other products.

FTSE Russell (the trading name of FTSE International Limited and Frank Russell Company) confirm that Santen Pharmaceutical has been independently assessed according to the index criteria, and has satisfied the requirements to become a constituent of the FTSE Blossom Index Series. Created by the global index provider FTSE Russell, the FTSE Blossom Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE Blossom Index are used by a wide variety of market participants to create and assess responsible investment funds and other products.

The inclusion of Santen Pharmaceutical in any MSCI index, and the use of MSCI logos, trademarks, service marks or index names herein, do not constitute a sponsorship, endorsement or promotion of Santen Pharmaceutical by MSCI or any of its affiliates. The MSCI indexes are the exclusive property of MSCI. MSCI and the MSCI index names and logos are trademarks or service of MSCI or its affiliates.